Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Diamond Biotechnology Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Diamond Biotechnology has a total shareholder equity of NT$612.6M and total debt of NT$301.9M, which brings its debt-to-equity ratio to 49.3%. Its total assets and total liabilities are NT$1.0B and NT$428.9M respectively. Diamond Biotechnology's EBIT is NT$98.7M making its interest coverage ratio 13.6. It has cash and short-term investments of NT$224.1M.
Anahtar bilgiler
49.3%
Borç/özkaynak oranı
NT$301.86m
Borç
| Faiz karşılama oranı | 13.6x |
| Nakit | NT$224.14m |
| Eşitlik | NT$612.55m |
| Toplam yükümlülükler | NT$428.90m |
| Toplam varlıklar | NT$1.04b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 6815's short term assets (NT$673.3M) exceed its short term liabilities (NT$231.8M).
Uzun Vadeli Yükümlülükler: 6815's short term assets (NT$673.3M) exceed its long term liabilities (NT$197.1M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 6815's net debt to equity ratio (12.7%) is considered satisfactory.
Borcun Azaltılması: 6815's debt to equity ratio has increased from 37.8% to 49.3% over the past 5 years.
Borç Kapsamı: 6815's operating cash flow is negative, therefore debt is not well covered.
Faiz Kapsamı: 6815's interest payments on its debt are well covered by EBIT (13.6x coverage).